原发性肺癌患者血清中相关肿瘤标志物表达水平的变化及其临床意义 |
| |
引用本文: | 许可. 原发性肺癌患者血清中相关肿瘤标志物表达水平的变化及其临床意义[J]. 实用癌症杂志, 2017, 0(6): 900-902. DOI: 10.3969/j.issn.1001-5930.2017.06.008 |
| |
作者姓名: | 许可 |
| |
作者单位: | 541002,广西壮族自治区南溪山医院 |
| |
摘 要: | 目的探讨肿瘤标志物[癌抗原125、CY211、癌胚抗原、鳞状细胞癌抗原(SCC)及神经原特异性烯醇化酶(NSE)]在原发性肺癌患者血清中的变化情况及意义。方法选取肺癌患者50例(甲组)、肺良性疾病患者50例(乙组)及健康人群50例作为研究对象,并采用化学发光法检测3组肿瘤标志物表达水平。结果甲、乙组各项肿瘤标志物水平明显高于健康人群组,差异具有统计学意义,P<0.05。甲组患者癌胚抗原(CEA)及CY211(cytokeratin-19-fragment,CY211)水平明显高于乙组(P<0.05)。与临床手术组织病理检查结果比较,小细胞肺癌患者神经原特异性烯醇化酶(neuron specific enolase,NSE)阳性率较其他类型肺癌高,而腺癌患者中癌抗原125(CA125)阳性率最高,鳞癌患者中CY211阳性率表达最高,P<0.05。结论检测肿瘤标志物,尤其是血清CEA、CY211,有助于肺癌诊断;同时检测不同肿瘤标志物还有利于肺癌的临床病理分型,从而可为临床治疗提供指导价值。
|
关 键 词: | 原发肺癌 肿瘤标志物 血清 病理分型 |
Change of Expression of Related Tumor Markers in Primary Lung Cancer and Clinical Significance |
| |
Abstract: | Objective To investigate the change of expression of related tumor markers [cancer antigen 125,CY211,carcinoembryonic antigen (CEA),squamous cell carcinoma antigen (SCC) and neuron-specific enolase (NSE)] in primary lung cancer and clinical significance.Methods 50 cases of lung cancer patients (Group A),50 cases of enign lung diseases (group B) and 50 cases of healthy people were selected,and tumor markers expression levels of the 3 groups were detected by chemiluminescence.Results Tumor marker levels of A,B groups were significantly higher than the healthy group,the difference was statistically significant,P < 0.05.CEA and CY211 levels of group A were significantly higher than group B,P < 0.05.Compared with surgical pathology and clinical findings,positive rate of NSE of small cell lung cancer patients was higher than other types of lung cancer,while adenocarcinoma patients had the highest positive rate of CA125,squamous cell carcinoma patients had the highest positive rate of CY211,P < 0.05.Conclusion Detection of tumor markers,especially serum CEA,CY211 can contribute to the diagnosis of lung cancer,simultaneous detection of different tumor markers is also beneficial to clinical pathologic staging of patients,which can provide guidance value for clinical treatment. |
| |
Keywords: | Primary lung cancer Tumor marker Serum Pathological classification |
本文献已被 维普 万方数据 等数据库收录! |
|